213 related articles for article (PubMed ID: 11109804)
1. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
[TBL] [Abstract][Full Text] [Related]
2. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of positron emission tomography in diagnosing and staging of lung cancer].
Zhu ZH; Zhou Q; Li LY; Cui RX; Cheng WY; Li YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):365-8. PubMed ID: 12940078
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
[TBL] [Abstract][Full Text] [Related]
6. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images.
Nomori H; Watanabe K; Ohtsuka T; Naruke T; Suemasu K; Uno K
Lung Cancer; 2004 Jul; 45(1):19-27. PubMed ID: 15196730
[TBL] [Abstract][Full Text] [Related]
8. PET in lung cancer staging.
Coleman RE
Q J Nucl Med; 2001 Sep; 45(3):231-4. PubMed ID: 11788815
[TBL] [Abstract][Full Text] [Related]
9. Thoracic FDG PET: state of the art.
Erasmus JJ; McAdams HP; Patz EF; Goodman PC; Coleman RE
Radiographics; 1998; 18(1):5-20. PubMed ID: 9460106
[TBL] [Abstract][Full Text] [Related]
10. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
11. PET in lung cancer.
Coleman RE
J Nucl Med; 1999 May; 40(5):814-20. PubMed ID: 10319756
[TBL] [Abstract][Full Text] [Related]
12. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
[TBL] [Abstract][Full Text] [Related]
13. Staging non-small cell lung cancer with whole-body PET.
Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
[TBL] [Abstract][Full Text] [Related]
14. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras.
Weber W; Young C; Abdel-Dayem HM; Sfakianakis G; Weir GJ; Swaney CM; Gates M; Stokkel MP; Parker A; Hines H; Khanvali B; Liebig JR; Leung AN; Sollitto R; Caputo G; Wagner HN
J Nucl Med; 1999 Apr; 40(4):574-8. PubMed ID: 10210215
[TBL] [Abstract][Full Text] [Related]
15. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis.
Dewan NA; Reeb SD; Gupta NC; Gobar LS; Scott WJ
Chest; 1995 Aug; 108(2):441-6. PubMed ID: 7634881
[TBL] [Abstract][Full Text] [Related]
16. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
17. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma?
Yap CS; Schiepers C; Fishbein MC; Phelps ME; Czernin J
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1166-73. PubMed ID: 12192561
[TBL] [Abstract][Full Text] [Related]
19. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
20. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion.
Gupta NC; Rogers JS; Graeber GM; Gregory JL; Waheed U; Mullet D; Atkins M
Chest; 2002 Dec; 122(6):1918-24. PubMed ID: 12475827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
